目的：探讨玻璃体腔注射雷珠单抗和康柏西普治疗渗出型年龄相关性黄斑变性(ARMD)疗效，并分析对患者最佳矫正视力(BCVA)、中心凹视网膜厚度(CRT)和并发症的影响。

方法：回顾性分析。收集2017-01/2020-01我院收治的渗出型ARMD患者60例60眼临床资料，按治疗药物不同分为玻璃体腔注射雷珠单抗组30眼和玻璃体腔注射康柏西普组30眼。比较两组患者治疗前，治疗1、2、3mo时患者BCVA、CRT、脉络膜新生血管变化和并发症发生情况。

结果：治疗后1、2、3mo，两组患者BCVA(LogMAR)较治疗前显著改善(P<0.05)，CRT较治疗前显著降低(P<0.05)，且玻璃体腔注射康柏西普组治疗1、2、3mo的CRT显著低于玻璃体腔注射雷珠单抗组(P<0.05)； 两组脉络膜新生血管恢复情况和并发症发生情况比较无明显差异(P>0.05)。

结论：玻璃体腔注射雷珠单抗和康柏西普治疗渗出型ARMD均可取得较好的疗效，二者在改善视力方面无明显差异，但康柏西普治疗渗出型ARMD在降低CRT方面更具有明显优势。

AIM: To explore the efficacy of intravitreal injection of ranibizumab and conbercept in the treatment of exudative age-related macular degeneration(ARMD), and analyze the effects on best corrected visual acuity(BCVA), central retinal thickness(CRT)and complications of patients.

METHODS: The clinical data of 60 patients(60 eyes)with exudative ARMD in the hospital between January 2017 and January 2020 were collected for retrospective analysis. According to different treatment drugs, they were divided into intravitreal injection of ranibizumab group(30 eyes)and intravitreal injection of conbercept group(30 eyes). The BCVA, CRT, choroidal neovascularization changes and occurrence of complications were compared between the two groups before treatment and 1, 2 and 3mo after treatment.

RESULTS: After 1, 2 and 3mo treatment, the BCVA(LogMAR)of patients in the two groups was better than that before treatment(P<0.05). The CRT was lower than that before treatment(P<0.05), and the CRT at 1, 2 and 3mo after treatment in intravitreal injection of conbercept group was lower than that in intravitreal injection of ranibizumab group(P<0.05). There were no significant differences in the recovery of choroidal neovascularization and the occurrence of complications between the two groups(P>0.05).

CONCLUSION: Both intravitreal injection of ranibizumab and conbercept can achieve a good efficacy in the treatment of exudative ARMD, and there was no significant difference in the improvement of visual acuity between them. However, conbercept has obvious advantages in reducing CRT in the treatment of exudative ARMD.